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Table 1 – Occurrence of genotypes, genotype frequency
and allele frequency of the CCR5 gene in Roraima, Brazil.
Genetic proﬁle Frequency
Patient (n = 117)
Genotype
CCR5/CCR5 106 (90.6%)
CCR5/CCR532 11 (9.4%)
CCR532/CCR532 0
Genotypic frequency
CCR5/CCR5 0.906
CCR5/CCR532 0.094
CCR532/CCR532 0
Allele frequency
r
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Dear Editor,
The expression of CCR5 gene, located on the short arm of chro-
mosome three (3p21.31), leads to the formation of a protein
that acts as a receptor for several chemokines.1 A deletion of 32
base pairs gives rise to an important Rs333 polymorphism. The
heterozygous genotype CCR5/32 produces partially func-
tional receptors while the homozygous recessive 32/32
features a non-functional receptor.2
Information about the prevalence of Rs333 is an essen-
tial aspect of medical decisions, mainly for CCR5 blockers
prescription to HIV patients. Furthermore, immunogenetics
studies that include the prevalence of CCR5 genes or other
genetic factors in the population of Roraima State, Brazil, were
not found in the literature.
To determine the prevalence of Rs333 polymorphism
located in the CCR5 gene, we  designed a cross-sectional
study with HIV-infected patients living in Roraima, who had
blood sent for analyses at the Central Laboratory of Roraima
State (LACEN/RR). The Ethics Research Committee (REC) from
the Federal University of Roraima (COEP/UFRR) approved this
research (CAAE number: 15629013.8.0000.5302). Subsequently,
5 mL  of blood samples were collected from 120 HIV-1 infected
patients between January 2014 and February 2014. Genomic
DNA was extracted using the automated system QIAcube,
with QIAamp DNABlood Kit (QIAGEN, Germany) followed by
PCR ampliﬁcation as described previously3 and agarose gel
electrophoresis. Three of these samples were rejected. Thus,
our sampling represents more  than 10% of all HIV-infected
patients, including patients from 12 out of 14 municipalities
in the Roraima state.
Two genotypes were found in this group of patients: 106
patients had CCR5/CCR5 represented by a single fragment of
137 bp, and 11 patients had CCR5/CCR532 characterized by
two fragments, one of 137 bp and another of 105pb. Neverthe-
less, the CCR532/CCR532 genotype was not found in this
study (Table 1).
Roraima is one of the newest states of the Brazilian Feder-
ation and one of the principal mining centers in the country
during the 80s and 90s, which attracted Brazilians from other
regions contributing to the population miscegenation.4 The
32 allele has its origin in Europe; in Brazil it has different fre-
quencies varying from 4.2% in the North region, to 6.4% in the
South and 0.2% in Native americans.5 That frequency in theCCR5 0.954
CCR532 0.046
North region, where Roraima is located, is similar to what was
found in this study (4.6%).
Due to the undoubted protective effect of CCR532 against
HIV infection and aids progress, that project was not designed
as an inference study to evaluate this marker as an immuno-
genic protective factor in Roraima’s HIV-infected patients.
Thus, healthy controls were not included. Yet, to our knowl-
edge, this is the ﬁrst study about the prevalence of immuno-
genetic factors in HIV-infected patients from Roraima State.
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